<DOC>
	<DOC>NCT01788696</DOC>
	<brief_summary>The purpose of this study is to evaluate the impact of imaging the brain as a diagnostic tool in the management of early Parkinson's disease (PD).</brief_summary>
	<brief_title>Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects</brief_title>
	<detailed_description>The imaging drug used in this study is Ioflupane (123I) Injection, also referred to as DaTscan. DaTscan is FDA approved.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>age 1880; diagnosis of idiopathic PD exhibiting at least 2 of 3 cardinal signs (bradykinesia, rigidity and resting tremor); maximum duration of previous exposure to antiparkinsonian therapy being &lt; 8 weeks; ability to signed informed consent; willingness and ability to complete medication diary and questionnaires; if a female subject of childbearing potential, the use of an effective method of contraception. current treatment with antiparkinsonian medication; previous treatment with antiparkinsonian medication for greater than 8 weeks; inability to complete questionnaires; unwillingness to complete all questionnaires and medication diary; subjects with secondary causes of parkinsonism; participant has evidence of clinical significant thyroid disease, gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other medical or psychiatric disorder; positive serum/urine pregnancy test at any time during the study period; the participant has a history of alcohol, narcotic, or any other drug abuse as defined by the DSMIV within the past 2 years; participation in a concurrent PD trial within 60 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Parkinsonism</keyword>
	<keyword>Idiopathic Parkinson Disease</keyword>
</DOC>